Evidence Hub

Role of Omega-3 Fatty Acids in Irritable Bowel Syndrome (IBS)

Javed Yakoob, Zaigham Abbas

International Journal of Pharmacological Research, 2016

1 citation

Abstract

Background: Dietary supplementation with Omega-3 (?-3) fatty acids (FAs) has been demonstrated to elicit several effects ranging from decrease in blood pressure, anti-arrhythmic effect and decrease in inflammation in inflammatory bowel disease, asthma and rheumatoid arthritis. Irritable bowel syndrome (IBS) is a chronic disorder characterized by abdominal pain and irregular bowel habit. It is associated with visceral hypersensitivity, increased mucosal permeability and a low-grade mucosal inflammation. Commercially available omega (?)-3 polyunsaturated fatty acids (PUFA) are being prescribed as empirical treatment for many chronic ailments including IBS. Aim: To examine literature available support use of ?-3 PUFA in IBS. Methods: We conducted a search using Omega 3 fatty acids supplementation on the PubMed, Scopus, and databases (e.g. MEDLINE, CINAHL, EMBASE, and Science Citation Index Expanded) from 1966 to December, 2015. Result: The gut microbiota in IBS is associated with an imbalance of Firmicutes/Bacteroidetes ratio. This imbalance has an impact on gas and metabolite production such as short chain fatty acids. Omega-3 FAs are anti-inflammatory, while ?-6 FAs are proinflammatory. Conclusion: The benefit of ?-3 FAs for IBS requires more clarification by prospective studies. Current claims of long chain PUFA supplementation in IBS should be viewed with caution

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free